- Conditions
- Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
- Interventions
- Thoracic, Abdominal, Custom Device, Illiac Artery
- Device
- Lead sponsor
- Vascutek Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 17
- States / cities
- Long Beach, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 8,625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1
- Interventions
- Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 916 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
- Conditions
- Graft Versus Host Disease (GVHD)
- Interventions
- Alpha-1 antitrypsin (AAT), Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
- Conditions
- Atopic Dermatitis, Type 1 Hypersensitivity
- Interventions
- STMC-103H, Placebo
- Biological
- Lead sponsor
- Siolta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Breast Cancer
- Interventions
- Vinorelbine, Trastuzumab, Avelumab, Utomilumab
- Drug
- Lead sponsor
- Adrienne G. Waks
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
- Interventions
- LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 42
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Springdale, Arkansas + 31 more
- Conditions
- Severe Sepsis
- Interventions
- Drotrecogin alfa (activated)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more
- Conditions
- Tricuspid Regurgitation
- Interventions
- TriClipTM Device
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Gastroesophageal Cancer, Adenocarcinoma
- Interventions
- Pembrolizumab, Abemaciclib
- Drug
- Lead sponsor
- Nataliya Uboha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Iowa City, Iowa • New Brunswick, New Jersey + 1 more
- Conditions
- Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
- Interventions
- radiation therapy, surgery, mFOLFIRINOX, FOLFOX
- Radiation · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 154
- States / cities
- Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2013
- U.S. locations
- 15
- States / cities
- Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more
- Conditions
- Lung Transplant
- Interventions
- Exercise
- Other
- Lead sponsor
- Indiana University Health Methodist Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Implementation Research, Depressive Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Conduct Disorders in Children, Pediatric Mental Health Services
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Colorectal Cancer Screening
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Non-Diabetic Patients, Wound Leg, Chronic Ulcer Leg/Foot
- Interventions
- Not listed
- Lead sponsor
- Chandan Sen
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Columbus, Ohio
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 78
- States / cities
- Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
- Conditions
- Amblyopia
- Interventions
- 4-hour AmblyZ glasses, 12-hour AmblyZ glasses, 2-hour patching, 6-hour patching
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 3 Years to 8 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 926 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- pictilisib, Placebo, bevacizumab, carboplatin, paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
- Conditions
- Adult Intracranial Neoplasm, Vascular: Intracranial
- Interventions
- Fluorescein Sodium
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Norfolk, Virginia
- Conditions
- Dupuytren's Disease
- Interventions
- Collagenase clostridium histolyticum
- Biological
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Rockford, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 13 Months to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
- Conditions
- Leukemia
- Interventions
- cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 30
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 23 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bermekimab, Adalimumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more